Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma

BACKGROUND: Preserving health-related quality of life (HRQOL) is an important goal during renal cell carcinoma treatment. We report HRQOL outcomes from a phase II trial (NCT03173560). PATIENTS AND METHODS: HRQOL data were collected during a multicenter, randomized, open-label phase II study comparin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergerot, Cristiane, Young Rha, Sun, Pal, Sumanta, Koralewski, Piotr, Stroyakovskiy, Daniil, Alekseev, Boris, Parnis, Francis, Castellano, Daniel, Lyun Lee, Jae, Sunela, Kaisa, Ciuleanu, Tudor, Heng, Daniel, Glen, Hilary, Wang, Jinyi, Bennett, Lee, Pan, Janice, O’Hara, Karen, Puente, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847563/
https://www.ncbi.nlm.nih.gov/pubmed/35881028
http://dx.doi.org/10.1093/oncolo/oyac142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847563/
https://www.ncbi.nlm.nih.gov/pubmed/35881028
http://dx.doi.org/10.1093/oncolo/oyac142

Ejemplares similares